Algeta as an investment
Algeta seeks to be an attractive investment for its shareholders through consistent performance and the accurate and timely distribution of information.
Algeta’s goal is to help cancer patients. It is an oncology company seeking to create new types of medicine – powerful in killing cancer cells – that can bring real benefit to cancer patients in areas of high need. In the phase III ALSYMPCA study of castration-resistant prostate cancer (CRPC) patients, Algeta’s compound radium-223 dichloride (radium-223) demonstrated an improvement in overall survival compared to placebo-treated CRPC patients.
Algeta has invested in its GMP (Good Manufacturing Practice) facility in Oslo, where radium-223 can be manufactured for worldwide distribution. The company is also forging connections across the US that, pending approval by the FDA, will introduce radium-223 to the country’s pharmaceutical market. Under the terms of the Bayer agreement, Algeta will be eligible to receive 50 percent of the profits attributable to sales of the drug in the US and will be responsible for 50 percent of the costs of its commercialization in this territory. Algeta is also eligible for milestone payments from Bayer, including EUR 50 million on first commercial sale of radium-223, as well as royalties on Bayer’s sales of radium-223 outside the US.
Algeta is also seeking to expand its alpha-pharmaceutical technology platform to target a broader range of cancers using other alpha-particle emitting elements, including thorium-227.
"Algeta thrives in an ecosystem of relationships in order to bring targeted medicines to patients"